Tifcemalimab is under clinical development by Shanghai Junshi Bioscience and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tifcemalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tifcemalimab overview

Tifcemalimab is under development for the treatment of recurrent/refractory malignant lymphoma, hodgkin lymphoma (b-cell hodgkin lymphoma), non-hodgkin lymphoma including follicular lymphoma, solid tumors including non-small cell lung cancer, melanoma, Hodgkin lymphoma, urothelial carcinoma, renal cell carcinoma, recurrent or metastatic head and neck squamous cell carcinoma, small cell lung cancer and nasopharyngeal carcinoma. It is a monoclonal antibody which is administered through intravenous route. It acts by targeting BTLA (B- and T-lymphocyte attenuator).

Shanghai Junshi Bioscience overview

Shanghai Junshi Bioscience (Junshi Bioscience) is a biopharmaceutical company that discovers, develops and commercializes drugs for infectious diseases, oncology, metabolic, auto-immunity and neurologic indications. It is investigating JS001 antibody against various malignant tumors; JS003, JS006, and JS201 to treat solid tumors; JS004 for melanoma, hodgkin lymphoma and lung carcinoma; JS101 for the treatment of breast cancer; JS108 for pancreatic, triple negative breast cancer, small cell lung cancer. The company is also evaluating JS002 against hyperlipidaemia; JS103 for hyperuricacidemia and gout disease; UPB1211 to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS010 for migraine; and JS016 against COVID-19. It operates with research and development centers in California and Maryland, the US. Junshi Bioscience is headquartered in Shanghai, China.

For a complete picture of Tifcemalimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.